2a) Our returning expert author is @Ron_Witteles, Professor of Cardiovascular Medicine & @StanfordMedRes IM program director, specialist in #amyloidosis, #sarcoidosis, and #CardioOncology. pic.twitter.com/oPBHjWGtYh
— cardio-met (@cardiomet_CE) November 13, 2025
3) This program is intended for #HCPs and is supported by an independent educational grant from Alnylam Pharmaceuticals. Statement of #accredition and faculty disclosures at https://t.co/gvXca4G9Xm. Follow this š§µfor š0.5 hr CE/#CME credit!
— cardio-met (@cardiomet_CE) November 13, 2025
5) For quick review, #ATTR_CM is formed by the deposition of misfolded #transthyretin (#TTR, also known as #prealbumin) protein in the heart muscle. This leads to the appearance of thickened heart walls & development of #arrhythmias, esp #Afib and heart block. pic.twitter.com/I3MHBhuVZg
— cardio-met (@cardiomet_CE) November 13, 2025
6b) For years, there were no #ATTR-specific treatments ā but that has thankfully changed. In the last 12 months, treatment options for ATTR-CM have expanded from 1 @US_FDA approved agent to 3; two are #TTR stabilizers & the other is a TTR gene #silencer.
— cardio-met (@cardiomet_CE) November 13, 2025
6d) It's d, #eplontersen. The first 3 agents are all approved for both wild-type & hereditary (AKA āvariantā) ATTR-CM. Eplontersen & #vutrisiran are approved for the related hereditary ATTR-#polyneuropathy, or #ATTR_PN.
— cardio-met (@cardiomet_CE) November 13, 2025
Letās take a deeper dive into these 3 agents for ATTR-CM.
8) #Acoramidis is another oral #stabilizer treatment w/strong efficacy in Ph 3 trial #ATTRibute-CM. Effectiveness of these meds shown by ā¬ļøof 50% in #CV hospitalizations for the group on acoramidis. The results ā”ļø @US_FDA approval late 2024.
— cardio-met (@cardiomet_CE) November 13, 2025
Seeš https://t.co/VgFpNjqqbD pic.twitter.com/GuG2H9oQku
9b) In the Ph 3 #HELIOS-B trial, #vutrisiran was tested vs placebo in pts w/ ATTR-CM, & showed great efficacy across all primary & secondary endpoints, including all-cause mortality & #CV events.
— cardio-met (@cardiomet_CE) November 13, 2025
10) At #AHA25, we learned new data on the approved agents, as well as data on some agents which are not yet @US_FDA approved but are in the pipeline. Letās dig inā¦ and experience that #NewOrleans spirit! pic.twitter.com/TUCqWat5gW
— cardio-met (@cardiomet_CE) November 13, 2025
11b) As #ATTR amyloid does not typically involve the kidneys, this likely results from improved #heartfailure #HF outcomes. pic.twitter.com/1m87GLnKp4
— cardio-met (@cardiomet_CE) November 13, 2025
13) The same goes for left atrial #LA strain ā it is predictive of adverse outcomes (including in #HELIOS_B), and #vutrisiran treatment in a substudy of that trial was associated with better LA strain values at month 30 than placebo. pic.twitter.com/GScIo7DnkC
— cardio-met (@cardiomet_CE) November 13, 2025
15a) More #TTR silencers are on the way! We expect to get results from the Ph 3 #CARDIO_TTRansform trial of #eplontersen next year. https://t.co/N9wfQ5SUAf
— cardio-met (@cardiomet_CE) November 13, 2025
16a) Back to #AHA2025.
— cardio-met (@cardiomet_CE) November 13, 2025
We also saw new interesting data on the #stabilizer #acoramidis. Letās take a look at some of the more interesting findingsā¦ pic.twitter.com/g5ObrV4Qzh
17) Another study looked at the benefit in #mortality & #CV hospitalization across a host of subgroups with #acoramidis, and again the message was clear: The effects were quite consistent across them all. Take a lookā¦ pic.twitter.com/LbrQvrJVJn
— cardio-met (@cardiomet_CE) November 13, 2025
19a) How about investigational agents? Let's look at #monoclonal antibodies #MAb. Prior Ph 1 data with #cliramitug was encouraging and that agent is now in a Ph 3 trial. At #AHA25 we saw new data from a Ph 2 trial of the MAb #coramitug (name confusion alert!šØ)
— cardio-met (@cardiomet_CE) November 13, 2025
19c) In short, a mixed bag ā it hit 1 of 2 primary endpoints (#NTBNP ā¬ļø at 12 mos). Those data showing a benefit with the higher dose #coramitug ā encouraging! Based largely on these results, a Phase 3 trial of coramitug (#CLEOPATTRA) has already begun. pic.twitter.com/9qvbfIJsHQ
— cardio-met (@cardiomet_CE) November 13, 2025
19e) #Safety was overall favorable, though with a possible increase in #arrhythmias in the #coramitug group. The take home here: reason for optimism, but a long ways to go before we can be confident that #MAbs have a favorable risk:benefit profile in #ATTR-CM. pic.twitter.com/lspWV7EEoK
— cardio-met (@cardiomet_CE) November 13, 2025
20b) In new data from the Ph 1 #ATTR_CM trial for #Nex-z, sustained TTR ā¬ļø of ~90% are seen out to 3yr after 1ā£dose, along with stability of cardiac #biomarkers. As there is no placebo in this trial, interpret clinical efficacy data with caution, but this is still encouraging. pic.twitter.com/tDwxLevqx6
— cardio-met (@cardiomet_CE) November 13, 2025
20d) This caused @US_FDA to recently put a pause on the study, and the future of this approach remains up in the air.https://t.co/h5Gdm1Ye5whttps://t.co/EtbmjAmXjY
— cardio-met (@cardiomet_CE) November 13, 2025
21b) In this interesting study presented at #AHA25 & published in @JAMACardio, an #AI model that analyzed #ECGs and #echocardiograms identified pts at high risk for the diagnosis, who were then contacted and offered screening.
— cardio-met (@cardiomet_CE) November 13, 2025
See š https://t.co/tUMQc4nq2f
21d) But look at those numbers! Only 50 out of 1471 eligible pts actually ended up getting screening, highlighting the real challenge of #AI-based screening protocols: implementation. Until that improves, wide adoption of even the best models will be challenging. pic.twitter.com/XEWfSWNLNW
— cardio-met (@cardiomet_CE) November 13, 2025
23) And you š«µcan do that RIGHT NOW! Point your š±ļøto https://t.co/LnnSRpUIb6 and claim your 0.5hr credit! Thanks so much to @Ron_Witteles for this excellent šš„program! pic.twitter.com/BsfEYs7naV
— cardio-met (@cardiomet_CE) November 13, 2025